Personalised prostate cancer therapy (BriaCell Therapeutics)

N/A

Report date: 2024/11/15 17:02:27

Base Information

Drug NamePersonalised prostate cancer therapy (BriaCell Therapeutics)
Drug Alias NameBria-Pros
ClassificationCell and gene therapy > Cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor modulatorsInterferon alpha replacements
TargetsGranulocyte-macrophage colony-stimulating factor receptorInterferon alpha
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBriacell Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesBriacell Therapeutics Corp
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A